Publication Cover
Redox Report
Communications in Free Radical Research
Volume 18, 2013 - Issue 3
1,110
Views
18
CrossRef citations to date
0
Altmetric
Research articles

Serum malondialdehyde levels, myeloperoxidase and catalase activities in patients with nephrotic syndrome

, , , , , & show all
Pages 107-112 | Published online: 15 Nov 2013
 

Abstract

Objectives

Some studies have indicated the pathophysiological importance of reactive oxygen species (ROS) in patients with nephrotic syndrome. Myeloperoxidase (MPO) is a leukocyte-derived enzyme-generating ROS that has been proposed to exert a wide array of pro-atherogenic effects throughout all stages of the atherosclerotic process. The aim of this study was to investigate the serum malondialdehyde (MDA) levels, MPO and catalase activities in patients with adult nephrotic syndrome.

Patients and Methods

Twenty-four patients with nephrotic syndrome and 24 healthy controls were enrolled. Serum MPO activity, catalase activity, and MDA levels were assessed.

Results

Serum MPO activity and MDA levels were significantly higher in patients with nephrotic syndrome than controls (both, P < 0.001), while catalase activity was significantly lower (P < 0.001). Serum catalase activity was found to be significantly correlated with MPO activity (r = −0.417, P = 0.003) and MDA levels (r = −0.532, P = 0.007). The serum MDA levels were also found to be significantly correlated with MPO activity (r = 0.419, P = 0.003).

Conclusions

We concluded that serum MPO activity and oxidative stress were increased and that serum catalase activity was decreased in patients with adult nephrotic syndrome. In addition, these results indicate that increased MPO activity is associated with an oxidant–antioxidant imbalance that may contribute to atherosclerosis in patients with adult nephrotic syndrome.

Acknowledgements

The authors thank the staff at the Harran University Clinical Biochemistry for their generous and friendly assistance in every step of this study.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.